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e.2012.04Abstract Background: Leishmaniasis is one of the neglected diseases included in the World
Health Organization’s list of the top guns of antimicrobial resistance. Miltefosine (MIL) was the
ﬁrst successful oral agent used against visceral leishmaniasis in India. As regards cutaneous leish-
maniasis (CL), multiple experimental and clinical studies have investigated its efﬁcacy in treatment
of New World CL, while only few trials have focused on Old World CL. Therefore, this work was
designed to study the efﬁcacy of MIL in experimental Old World CL caused by Leishmania major
(MHOM/IL/81/FEBNI), one of the causative species of CL in the Middle East.
Results: Groups of infected mice were given MIL orally, at a dose of 20 mg/kg/day for 20 days.
Results showed that untreated infected mice suffered from autoamputation of the inoculated foot-
pads. While, those treated with MIL showed complete clinical cure, signiﬁcant reduction of parasite
burden and improvement of the histopathological changes of the cutaneous lesions. The drug causes
evident ultrastructural morphological alterations of L. major amastigote form. One month post-
treatment, no clinical sings of relapse were observed, and parasite density continued to decrease
signiﬁcantly.
Conclusion: The present study revealed activity of MIL against experimental Old World CL in the
mouse model caused by L. major (MHOM/IL/81/FEBNI), one of the causative species of CL in the
Middle East.
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.0031. Introduction
Protozoan diseases of different types lie among the major
worldwide health problems, especially in the poorest popula-
tions. Leishmaniasis, caused by several species of ﬂagellated
protozoa belonging to the genus Leishmania of the family
Trypanosomatidae, represents one of these threats [1,2]. Clinical
manifestations may include single self-healing or disseminatedand hosting by Elsevier B.V. All rights reserved.
262 M.M. Eissa et al.cutaneous lesions, mucocutaneous destruction and visceral
commitment, all resulting from Leishmania replication within
mononuclear phagocytes [3].
In the last decade, regions that are endemic for leishmania-
sis have expanded signiﬁcantly. Leishmaniasis is now endemic
in 88 countries, 72 of which are in developing countries, and 13
are among the least developed ones [4]. It is estimated that
worldwide 12 million people are affected by leishmaniasis; this
ﬁgure includes cases with overt disease and those with no
apparent symptoms [2].
Parasites of the genus Leishmania have a dimorphic lifecy-
cle, alternating between the motile ﬂagellated promastigote
and the intracellular amastigote. Once inside the host, the
promastigotes are internalized by tissue macrophages, where
they differentiate into non-motile amastigotes. These amastig-
otes are the major target of chemotherapy for leishmaniasis [5].
Currently, the genomic sequence of Leishmania has provided a
rich source of vaccine trials. Nevertheless, as yet no effective
vaccines against leishmaniasis are available and control of
the disease relies primarily on chemotherapy [6,7]. Anti-leish-
manial chemotherapy is currently limited to a few compounds
such as the pentavalent antimonials glucantime (N-methylglu-
camine antimoniate) and pentostam (sodium stibogluconate),
amphotericin B, paramomycine, and pentamidine. Pentavalent
antimonials have been the ﬁrst-choice drugs for leishmaniasis
treatment since the 1920s. Although they are generally effective
against most leishmaniasis cases, severe side effects are often
observed. These include hazards of parenteral administration,
long courses of treatment, toxic side effects and high costs.
Furthermore, the emergence of antimony-resistant strains
has been reported [8–10]. The high toxicity of the antimonial
formulation has been implicated in the death of several pa-
tients under treatment [11].
Miltefosine (1-O-hexadecylphosphocholine, MIL), which is
an alkylphosphocholine, registered as Impavido, is a simple
molecule, very stable, relatively safe, and was highly efﬁcient
in clinical trials [12]. MIL was originally developed as an anti-
cancer agent [13]. Then came the evidence of MILs excellent
anti-leishmanial activity both in vitro and in experimental ani-
mals [14–16]. Phosphocholines are slowly metabolized by phos-
pholipases to form products such as choline and long-chain
alcohols that are physiological metabolites and can be recycled
into phospholipids [12]. MIL is degraded rather slowly in vivo,
with an extended half-life, this may allow treatment with a few
doses. Being an oral drug with long half-life gave it the potential
to be one component of anti-leishmanial combination chemo-
therapy. Combination chemotherapy makes the treatment of
leishmaniasis more effective, attractive and available to all sec-
tions of the society. This also improves compliance, and pro-
longs the useful therapeutic life-span of the drugs [17,18].
Currently, MIL is the ﬁrst oral drug licensed for the treat-
ment of VL. As such, it represents a major advance in that it
makes home treatment possible, with the advantage of large-
scale use, by avoiding the expense and inconvenience of hospi-
talization, which makes it an attractive alternative [19]. Given
daily under medical supervision for four weeks, it cures 94–
97% of patients (both children and adults), is reasonably safe,
and is successfully used to treat cases resistant to antimonials
[20]. MIL has great potential for improving access to treatment
and overall control of VL and will be critical in the VL elimi-
nation campaign in the Indian subcontinent, and can be rec-
ommended for treatment of VL in Ethiopia [21].Multiple experimental and clinical studies have investigated
MILs efﬁcacy in treatment of New World cutaneous leishman-
iasis (CL) [22–24]. In vitro data showed that not all subspecies
of the Leishmania parasite have the same sensitivity to MIL,
this indicates that the response of leishmaniasis to treatment
with MIL seems to be variable, depending on several factors
such as, the causative species, different strains of each species
and the affected geographical areas. Given the variable re-
sponse between subspecies and geographical areas, thus it is
evident that chemotherapy of CL needs to be evaluated in each
endemic region, even if the ‘‘same’’ species of Leishmania
causes disease in these locales [25,24].
For unusual forms of the disease that require long period of
treatment such as diffuse cutaneous leishmaniasis, Zerpa et al.,
2007, found that MIL produced a dramatic clinical and para-
sitological response in those patients and improvement contin-
ued during drug administration but they relapsed later [26]. As
regards efﬁcacy of MIL against Old World CL (in Middle East
and Indian subcontinent) where the parasites responsible are
Leishmania tropica and Leishmania major subspecies, only little
information has recently become available [27,28]. In view of
its promising value against a number of Leishmania species,
the present work was carried out to investigate its efﬁcacy in
a controlled study against experimental Old World CL caused
by L. major (MHOM/IL/81/FEBNI), one of the causative spe-
cies of CL in the Middle East.
2. Material and methods
2.1. Leishmania strain and its maintenance
TheLeishmania strain used in this study was L. major (MHOM/
IL/81/FEBNI). It was kindly provided by Prof. Dr. Tamas Las-
kay (Professor of Immunology, Innate Immunity Research
Unit, Institute for Medical Microbiology and Hygiene, Univer-
sity of Lu¨beck, Germany). It was further maintained in the
Laboratory of Medical Parasitology Department, Faculty of
Medicine, Alexandria University, Alexandria, Egypt, both
in vitro onN.N.N. medium and in vivo by serial passage in Swiss
strain albino mice.
2.2. Culture media
N.N.N. medium was used for in vitro maintenance of the L.
major strain and mass cultivation of leishmania required for
animal inoculation [29].
2.3. Drug
Miltefosine (Virbac): milteforan 2% veterinary oral solution
was used. It was kindly supplied by Dr. Paolo Bianciardi, Sci-
entiﬁc Advisor, Virbac, Italy.
2.4. Experimental animals
All animal studies presented here have been approved by was
approved by the ethics committee of Faculty of Medicine,
Alexandria University, Egypt. All animal experiments comply
with national regulations for animal experimentation. Eighty
laboratories bred Swiss albino mice, 4–6 weeks old were used.
They were kept in separate cages in air conditioned rooms.
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Water was also supplied. For animal inoculation, promastig-
otes of L. major were harvested from N.N.N. medium on the
7th day of culture. The parasites were adjusted to the required
concentration of 20 · 106, and inoculated into the right hind
footpad. They were categorized into two main groups.
2.4.1. Group I: Control group
Forty mice were used as a control. This group was subdivided
into two equal subgroups:
2.4.1.1. Group (Ia): Normal non-infected control group. Ani-
mals were injected intradermally with 0.1 ml of sterile saline
in the right hind footpad.
2.4.1.2. Group (Ib): Infectednon-treated control group. Animals
of this group were infected by intradermal injection of 20 · 106
stationary-phase promastigotes into the right hind footpad
[30].
2.4.2. Group II: Experimental group: Infected treated group
Forty mice were infected by intradermal injection of 20 · 106
stationary-phase promastigotes into the right hind footpad
[30]. They were treated with MIL starting from the third week
post-infection. MIL was given orally at a dose of 20 mg/kg/day
for 20 days [24]. Animals of this group were further subdivided
equally into two subgroups according to the time of sacriﬁce.
2.4.2.1. Group (IIa). This group was sacriﬁced at the end of
treatment [31].
2.4.2.2. Group (IIb). This group was sacriﬁced one month after
the end of treatment.
The control subgroups (Ia, Ib) were sacriﬁced simulta-
neously as well.
2.5. The efﬁcacy of MIL was assessed by the following
parameters in comparison to infected non-treated control
2.5.1. Skin lesions
Observation of the inoculated footpad for the progression of
the cutaneous lesion development as regards redness, swelling,
crust formation, ulceration, gangrene and autoamputation
[30].
2.5.2. Parasitological study
Through the following.
2.5.2.1. Quantitative grading of Leishmania in the cutaneous
lesions. Impression smears were made from cutaneous lesions
of infected and infected treated groups. Smears were ﬁxed with
methanol, stained with Giemsa stain for examination under oil
immersion lens. The parasite density in the stained smear was
examined under oil immersion, and was recorded on empirical
scale as follows [32]:
Grade 6+: >100 parasites/ﬁeld.
Grade 5+: 10–100 parasites/ﬁeld.
Grade 4+: 1–10 parasite/ﬁeld.
Grade 3+: 1–10 parasite/10 ﬁelds.Grade 2+: 1–10 parasite/100 ﬁelds.
Grade1+: 1–10 parasite/1000 ﬁelds.
Grade 0+: No parasite/1000 ﬁelds.
2.5.2.2. Culture. Culture was performed to detect the presence
of viable parasites in the lesions. The footpads of infected and
infected treated groups were sterilized with 70% ethyl alcohol.
The footpads were sliced longitudinally into small parts under
complete sterile technique. These parts were cultured asepti-
cally on N.N.N. medium and kept at 23–25 C. The culture
was recorded as negative if no parasite was observed till the
10th day of culture.
2.5.3. Histopathological study
Portions of the cutaneous lesions from all groups were ﬁxed in
10% formalin, embedded in parafﬁn and cut into sections of
5 lm each. They were stained with hematoxylin and eosin
stain.
2.5.4. Transmission electron microscope (TEM) study
Parts of the cutaneous lesions were sliced into strips about
1 · 1 · 1 mm in cold 1.5% glutaraldehyde ﬁxative, and pro-
cessed for estimation by JOEL TEM [33].3. Results
Clinically, cutaneous lesions in all infected subgroups (Ib, IIa
and IIb) started with redness and swelling at the site of inoc-
ulation on the 7th day post-infection (Fig. 1a and b). Swell-
ing increased progressively onwards, crust formation of the
footpads occurred only in the infected non-treated control
mice (subgroup Ib) at the 5th week post-infection (Fig. 2a).
Subsequently, cutaneous ulcers were developed and slowly
increased in size (Fig. 2b and c), then gangrene started to de-
velop by the 7th week post-infection. At ﬁrst it was partial,
involving one or few digits or parts of the footpad. Later
on, it extended to involve the whole foot (Fig. 2d) and termi-
nated by auto amputation of the inoculated feet by the 8th
week post-infection in all survived mice (Fig. 2e). No crust
formation, ulceration, gangrene, or autoamputation were ob-
served in the infected treated subgroups (IIa and IIb).
Footpad thicknesses were measured weekly for the studied
groups, and their mean was calculated (Table 1). The mean
footpad thickness of the normal non-infected control mice
(subgroup Ia) was increased gradually to16.6 ± 0.7 mm at
the 10th week of the experiment. In subgroup Ib, it could
not be measured after the 5th week post-infection due to ulcer-
ation, gangrene and autoamputation of the foot.
Regarding mice of the infected treated subgroups (sub-
groups IIa and IIb), the swelling increased progressively till
the 3rd week post-infection, miltefosine was given at that time.
It was observed that footpad swelling started to decrease grad-
ually after the onset of treatment regimen. There was statisti-
cally signiﬁcant decrease in the mean footpad thickness of
infected treated subgroups (IIa and IIb) in comparison to the
infected non-treated controls. The swelling continued to de-
crease, and the mean values of footpad thickness signiﬁcantly
diminished to 16.8 ± 0.9 mm and, 17.4 ± 0.9 mm in sub-
groups IIa and IIb, respectively, at the 5th week post-infection
(two weeks after the treatment onset). From the 6th till the
Plate 1 Gross appearance of inoculated footpads of infected (subgroup Ib) and infected treated mice (subgroup IIa and IIb). Fig. (1)
Inoculated footpad of an infected mouse (subgroup Ib) at the 7th day post-infection showing redness and swelling. Fig. (2) Inoculated
footpad of an infected untreated mouse (subgroup Ib) showing: (a) crust formation, (b and c) ulcer formation, (d) gangrene extending to
involve the whole foot, (e) autoamputation of the inoculated footpad. Fig. (3) Infected mouse treated with miltefosine (subgroup IIb)
showing grossly normal inoculated footpad.
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for infected treated subgroups couldn’t be compared to those
of the infected non-treated controls (Table 1). At the end of
treatment (6th week post-infection), subgroups’ IIa and IIb
footpads became grossly normal with no clinical relapse one
month post-treatment (subgroup IIb) (Fig. 3). There was no
statistically signiﬁcant difference between the mean footpad
thickness of normal non-infected control subgroup and the in-
fected treated subgroups; neither at the 6th week post-infection
nor one month later.
Parasitologically, impression smears prepared from the in-
fected non-treated control subgroup (Ib) (Fig. 4). There was
statistically signiﬁcant decrease in the mean grades of parasite
density of the infected treated mice as compared to the infected
non-treated controls (subgroup Ib) whether sacriﬁced immedi-
ately at the end of treatment regimen (subgroup IIa), or onemonth later (subgroup IIb) (Table 2) ( Fig. 5). Moreover,
treatment with MIL didn’t lead to sterile cure of lesions and
Leishmania was shown to remain present and viable as demon-
strated by their ability to grow in culture in both treated
subgroups.
Examination of H&E stained sections of the infected non-
treated control mice sacriﬁced at the 6th week post-infection
(subgroup Ib) showed surface epithelial ulcerations and areas
of intact epidermis. There was a moderately dense, localized
dermal inﬁltrate composed of mixed acute and chronic non-
speciﬁc inﬂammatory cellular inﬁltrates which were com-
posed of macrophages admixed with lymphocytes and neu-
trophils. Congested dilated blood vessels were observed and
numerous Leishmania amastigotes were seen either inside
or outside the macrophages (Fig. 6a–c). At the 10th week
post-infection (subgroup Ib), there was intense dermal
Table 1 Effect of miltefosine on the mean footpad thickness of infected treated subgroups compared to their corresponding controls.
Timing 
Non-infected 
control mice 
(I-a)(n0=20) 
Infected non-
treated control 
mice  
(I-b)(n0=20) 
Infected 
treated mice, 
sacrificed at 
treatment end 
(II-a)(n0=20) 
Infected  
treated mice, 
sacrificed  one  
month after 
treatment  
(II-b)(n0=20) 
1st week Min-
Max, M±SD  
(n=20)  
13-15, 14.0±0.8 
(n=20)  
15-17, 15.7±0.6 
(n=20)  
15-17, 15.6±0.7 
(n=20)  
15-17, 15.9±0.7 
Significance  F = 30.976*  “LSD 5% = 0.445” I-b, II-a, II-b I-a I-a I-a 
2nd week Min-
Max, M±SD  
(n=20)  
13-15, 14.0±0.8 
(n=20)  
16-18, 16.9±0.8 
(n=20)  
16-19, 17.0±1.0 
(n=19)  
16-19, 17.2±0.8 
Significance  F = 62.948*   “LSD 5% = 0.555” I-b, II-a, II-b I-a I-a I-a 
3rd week Min-
Max, M±SD  
(n=19)  
13-16, 14.7±0.8 
(n=19)  
19-26, 21.3±2.0 
(n=20)  
18-25, 20.8±1.9 
(n=19)  
19-23, 20.7±1.2 
Significance  F = 76.488*  “LSD 5% =1.013” I-b, II-a, II-b I-a I-a I-a 
4th week Min-
Max, M±SD  
(n=18)  
14-16, 14.8±0.7 
(n=18)  
20-26, 23.1±1.7 
(n=19)  
17-20, 18.5±1.1 
(n=18)  
17-21, 18.6±1.0 
Significance  F = 148.898*  “LSD 5% = 0.787” I-b, II-a, II-b I-a, II-a, II-b I-a, I-b I-a, I-b 
5th week Min-
Max, M±SD  
(n=17)  
15-16, 15.6±0.5 
(n=18)  
19-26, 22.8±1.7 
(n=18)  
16-18, 16.8±0.9 
(n=18)  
16-19, 17.4±0.9 
Significance  F = 150.214*  “LSD 5% = 0.738” I-b, II-a, II-b I-a, II-a, II-b I-a, I-b I-a, I-b 
6th week Min-
Max, M±SD  
(n=17)  
15-17, 16.1±0.7 
- (n=17)  
15-17, 16.2±0.8 
(n=18)  
15-18, 16.6±0.9 
Significance  F = 1.521  “LSD 5% = 0.559” 
- - - - 
7th week Min-
Max, M±SD  
(n=17)  
15-17, 16.1±0.8 
- - (n=17)  
15-18, 16.3±1.0 
t (p) 0.729 (0.471) 
8th week Min-
Max, M±SD  
(n=16)  
16-17, 16.3±0.4 
- - (n=17)  
15-18, 16.1±0.8 
t (p) 0.899 (0.376) 
9th week Min-
Max, M±SD  
(n=16)  
16-17, 16.3±0.4 
- - (n=17)  
15-17, 16±0.7 
t (p) 1.5  (0.144) 
10th week 
Min-Max, 
M±SD  
(n=15)  
16-18, 16.4±0.7 
- - (n=16)  
15-17, 15.9±0.8 
t (p) 1.84  (0.076) 
n0: initial number of studied mice, n: number of survived mice, Min–Max: minimum–maximum, M: mean, SD: standard deviation, F: F test
(ANOVA), LSD: least signiﬁcant difference, t: Student’s t-test.
*Signiﬁcant at P 6 0.05.
Plate 2 Impression smears from cutaneous lesions of infected and infected treated mice. Fig. (4) Impression smear from cutaneous lesion
of infected untreated mouse showing parasite density grade 5+ (Giemsa ·1000). Fig. (5) Impression smear from cutaneous lesion of
infected treated mouse showing parasite density grade 3+ (arrow) (Giemsa ·1000).
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Plate 3 Light micrograph (LM) of cutaneous lesions of infected (subgroup Ib) and infected treated mice (subgroup IIa) at the 6th week
post-infection. Fig. (6) LM of skin of infected untreated mouse (subgroup Ib) at the 6th week post-infection showing epidermal ulceration
overlying dense acute and chronic non-speciﬁc inﬂammatory cellular inﬁltrate, congested dilated blood vessels and numerous Leishmania
amastigotes (a) H&E ·200, (b) H&E ·400, (c) H&E ·1000. Fig. (7) LM of skin of infected treated mouse (subgroup IIa) at the 6th week
post-infection showing an intact epidermis with a moderately dense inﬁltrate of chronic non-speciﬁc inﬂammatory cells and few visible
Leishmania amastigotes (a) H&E ·200, (b) H&E ·400, (c) H&E ·1000.
Table 2 Effect of miltefosine on the mean grade of parasite density of the infected treated subgroups compared to the infected non-
treated controls.
Timing Infected non-
treated control 
mice sacrificed 
at treatment end 
(I-b1) (n0=10) 
Infected non-
treated control 
mice sacrificed 
one month 
later  (I-b2) 
(n0=10) 
Infected 
treated mice, 
sacrificed at 
treatment end 
(II-a) (n0=20) 
Infected  
treated mice, 
sacrificed  one  
month after 
treatment  
(II-b) (n0=20) 
6th week  
Min-Max, 
 M±SD  
(n=8)  
5-6,  
5.63 ± 0.52 
- (n=17)  
3-5,  
3.53 ± 0.80 
- 
t (p) 6.75 (P<0.0001) * 
10th week 
Min-Max, 
M±SD  
- (n=7)  
5-6, 
 5.43 ± 0.53 
- (n=16)  
1-4, 
 2.50 ± 1.15 
t (p)  4. 98 (P<0.0001) * 
n0: initial number of studied mice, n: number of survived mice, Min–Max: minimum–maximum, M: mean, SD: standard deviation, t: Student’s t-
test.
*Signiﬁcant at P 6 0.05.
266 M.M. Eissa et al.inﬁltrate which was seen extending to the deeper layers of
the footpad involving the muscle layer (Fig. 8a–c). The ﬁnd-
ings of the infected treated mice sacriﬁced immediately at theend of treatment (at the 6th week post-infection – subgroup
IIa), showed an intact epidermis with a moderately dense
inﬁltrate, and the intensity of the infection was less than that
Plate 4 LM of cutaneous lesions of infected (subgroup Ib) and infected treated mice (subgroup IIb) at the 10th week post-infection.
Fig. (8) LM of skin of infected untreated mouse (subgroup Ib) at the 10th week post-infection showing an intense non-speciﬁc
inﬂammatory cellular inﬁltrate involving the muscle with numerous amastigotes (a) H&E ·200, (b) H&E ·400, (c) H&E ·1000. Fig. (9)
LM of skin of infected treated mouse (subgroup IIb) at the 10th week post-infection showing mild inﬂammatory inﬁltrate with scarcity of
the organisms (a) H&E ·200, (b) H&E ·400, (c) H&E ·1000.
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fected treated mice that were sacriﬁced at the 10th week
post-infection (one month after stoppage of treatment – sub-
group IIb) showed essentially a milder grade of affection in
terms of both the inﬂammatory response as well as the num-
bers of visible amastigotes (Fig. 9a–c).
Ultrathin sections of infected non-treated controls (sub-
group Ib) showed numerous Leishmania amastigotes. They
were seen extracellularly near the macrophage cells and
intracellularly inside parasitophorous vacuole ranging in num-
ber from 2 to 10 organisms per vacuole (Fig. 10a). Amastigotes
were generally spherical or slightly ovoid having spherical
nucleus with heterochromatin on the inner surface of the nu-
clear membrane, and a visible nucleolus ( Fig. 10b). There
was intact parasite electron dense plasma membrane with sub-
pellicular microtubules (Fig. 10c). Mitochondria and ﬂagellar
pocket of the amastigote were also observed (Fig. 10d). In
the infected treated mice (subgroup IIa), TEM showed
mono-nucleated amastigotes with disintegrated plasma mem-
brane (Fig. 11a), disappearance of subpellicular microtubules
( Fig. 11b), numbers of non-membrane bounded cavities
together with normal mitochondria (Fig. 11c). In addition,
absence of the nuclear envelop and abnormal nuclear chroma-
tin distribution was detected as well ( Fig. 11d). Moreover,pyknosis of the nucleus of the phagocytic cell was further ob-
served (Fig. 11e).
4. Discussion
For extending the range of leishmanial species that may poten-
tially be targeted by alkyl-PC drugs, the effect of miltefosine
on cutaneous leishmaniasis caused by L. major (MHOM/IL/
81/FEBNI) was demonstrated experimentally in this study.
In the present work, oral treatment regimen with MIL
started three weeks post-infection, a time interval that allowed
establishment of the infection and during which the inoculated
sites became swollen and inﬂamed. Besides, subsequent patho-
logical changes would be irreversible. The timing for treatment
initiation can signiﬁcantly inﬂuence the disease outcome as
stressed by previous studies [34]. By the end of treatment
course, cutaneous lesions became grossly normal with the
reduction of parasite burden. One month after treatment stop-
page, no clinical sings of relapse were observed, and the para-
site density continued to decrease signiﬁcantly denoting that
the leishmanicidal effect of MIL extended for a long period
after the end of treatment course. This could be attributed to
the long elimination half-life of MIL. It was reported that it
has a ﬁrst elimination half-life of about seven days and a ter-
Plate 5 Transmission electron micrograph (TEM) of cutaneous lesions of infected mice (subgroup Ib) at the 6th week post-infection.
Fig. (10) TEM of leishmanial lesion of infected untreated mouse (subgroup Ib) showing (a) three intracellular amastigotes (arrow) and an
extracellular one (EC) (·7500), (b) normal amastigote plasma membrane (M), nucleus (N) with its heterochromatin (arrow), and nucleolus
(n) (·20000), (c) High magniﬁcation showing parasite plasma membrane (M), subpellicular microtubules (MT) (x50000), (d) Parasite
mitochondria (MC), ﬂagellar pocket (FP) (x20000).
268 M.M. Eissa et al.minal one of about 30 days [35]. Aguiar et al., 2009, investi-
gated the activity of MIL alone, given at a dose of 25 mg/kg/
day for the treatment of experimental cutaneous leishmaniasis
caused by L. major versus its combination with topical 10%
paromomycin gel twice a day for 10 days. They reported that
combination therapy induced a statistically signiﬁcant reduc-
tion in lesion size and parasite burden in the skin, with com-
plete healing of ulcers, as compared with those treated with
oral miltefosine alone. This difference can be explained by
the longer duration of therapy (20 days) used in the present
study [36]. This work reported that, parasitological cure could
not be achieved in MIL treated L. major-infected mice in spite
of development of complete clinical cure. This coincides with
Mohebali et al., 2007, who reported parasitologically positive
smears for Leishmania amastigotes in four out of 28 patients
at the end of treatment of CL caused by L. major with oral
MIL in Iran [37]. In contrary, Filho et al., 2008, made a com-
parative study between oral MIL and parenteral N-methyl
glucamine antimoniate for treatment of experimental CL
caused by L. amazonensis, and reported that impression smears
of all mice treated with MIL were negative for Leishmania
amastigotes at the end of treatment [24].
In the current study, N.N.N. cultures were positive for
Leishmania promastigotes in all infected subgroups, whether
treated or not, at the 6th week post-infection and one month
later. These ﬁndings are in agreement with Schubach et al.,
1998, who isolated Leishmania parasite from a culture medium
inoculated with material taken from scar biopsy from two pa-
tients eight and 11 years after treatment of American CL with
pentavalent antimonials [38]. In addition, Sampaio et al., 2007,
reported positivity of cultures inoculated with material aspi-
rated from footpads of L. amazonensis-infected mice after
treatment with subcutaneous glucamine associated with topi-cal MIL [39]. In contrary, Filho et al., 2008, reported culture
negativity for L. amazonensis promastigotes in all mice treated
with MIL [24].
Results of the current study showed that MIL was able to
induce clinical cure in all treated mice, however parasitological
cure could not be achieved. Clinical evaluation is a method of
low precision since the presence or absence of the cutaneous le-
sions is not always coincides with the presence and the quan-
tity of parasites; big and disﬁguring mucous membrane
lesions may present small numbers of parasites whereas healed
cutaneous lesions may present Leishmania bodies [40]. Besides,
Ott et al., 1999, reported that most of Leishmania mexicana-in-
fected mice relapsed after treatment with topical MIL [41]. In
addition, Calvopina et al., 2006, demonstrated reappearance of
the cutaneous lesions caused by L. mexicana (New World
DCL) after stopping MIL in spite of good clinical response
during drug administration [40]. Furthermore, Zerpa et al.,
2007, revealed the development of new skin lesions following
MIL suspension in New World DCL patients after showing
dramatic clinical improvement [26]. Sundar et al., 2002, de-
ﬁned parasitological cure of leishmaniasis either as the absence
of parasites at the end of therapy, or a parasite density of grade
1+ with no parasites on repeated smears one month later dur-
ing six months of follow-up [20]. However, Several studies re-
vealed that the intracellular Leishmania organisms could
neither be entirely eradicated by anti-leishmanial chemother-
apy nor through T-cell-dependent, cytokine-driven acquired
resistance mechanisms [42,38].
Histologically, The evolution of Old World CL in mice was
attributed to aggregation of the infected macrophages at the
site of intradermal inoculation after which granulocytes and
lymphocytes appeared and ulceration occurred as supported
by Bray, 1987, and Eissa et al., 2003 [43,44], Besides, Verkat-
Plate 6 TEM of cutaneous lesions of infected treated mice (subgroup IIa) at the 6th week post-infection. Fig. (11): TEM of leishmanial
lesion of infected treated mouse (subgroup IIa) showing (a) Leishmania amastigote with disintegration of plasma membrane (arrow)
(x20,000), (b) disappearance of subpellicular microtubules (arrow) (·50,000), (c) non-membrane bounded cavities (C), normal parasite
mitochondria (MC) (·13,000), (d) absent amastigote’s nuclear envelope (arrow) with abnormal heterochromatin distribution (HC)
(·20,000), (e) Pyknosis of the phagocytic cell nucleus (P) (·7500).
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patterns for localized CL in Oman, among them the pattern
of diffuse dermal inﬁltrate composed predominantly of macro-
phages with an admixture of few polymorphs, lymphocytes
and occasionally plasma cells [45]. Congested dilated blood
vessels were observed, this could be a compensatory mecha-
nism to overcome the interference of the blood supply by the
inﬂammatory cellular inﬁltration.
Hematoxylin and eosin-stained sections taken from foot-
pads of infected treated mice showed an intact epidermis with
remarkable reduction in terms of the inﬂammatory response as
well as the number of detected parasites. These ﬁndings were
similar to those reported by Eissa et al., 1997, and 2011, where
they revealed reduction in the number of amastigotes and the
inﬂammatory reaction in experimental Old World CL caused
by L. major after treatment with dapsone and tamoxifen
respectively [46,30]. However, none of researchers who con-
ducted studies on the efﬁcacy of MIL in CL reported its histo-
pathological impacts upon the cutaneous lesions.
Electron microscopy is an important approach for conﬁrm-
ing the postulated drug–target interactions. Indeed, Leish-
mania have special organelles that are involved in metabolic
pathways, which are very distinct from those in mammalian
cells; these organelles are potential drug targets. Scanningand transmission electron microscopy can identify not only
the target organelles but also alterations to the cell surface
and ultrastructural changes that characterize distinct forms
of programed cell death [47]. Like other alkyl-PCs the mecha-
nism of action of MIL is only partly known; most data are in
tumor cell lines as an anti-cancer agent where these com-
pounds can trigger programed cell death (apoptosis) [48–50].
In tumor cells, the lipophilic alkyl-PCs primarily inﬂuence
membrane physiology in a pleiotropic ways, without interact-
ing with DNA. They could modulate membrane permeability
and ﬂuidity, membrane lipid composition, metabolism of
phospholipids and proliferation signal transduction [51,52].
Prior studies provided evidence that apart from its direct tox-
icity against the Leishmania parasite, MIL also modulates im-
mune cells such as macrophages, leading to parasite
elimination via oxidative radicals [53].
Data obtained in this study showed that amastigote forms
of L. major underwent remarkable morphological and ultra-
structural alterations upon treatment, compared with un-
treated groups. In infected treated mice, TEM examination
revealed disintegration of the amastigote plasma membrane
with partial disappearance of subpellicular microtubules and
absence of the nuclear envelop. This could be attributed to
the inhibitory action of MIL on sterol biosynthesis, phospho-
270 M.M. Eissa et al.lipid and ether–lipid metabolism which are important compo-
nents of the plasma membrane and so the nuclear membrane
of Leishmania parasite [54,24]. In contrary, Santa-Rita et al.,
2004, found that MIL affected the membrane integrity with
no effect on subpellicular microtubules of L. amazonensis
amastigotes [55]. All detected amastigotes were mono-nucle-
ated with abnormal chromatin distribution, this coincides with
Verma and Dey, 2004, who suggested that condensation of nu-
clear material in L. donovani parasite represents a part of pro-
cess leading to apoptosis-like death in response to MIL
treatment [42]. On the other hand, Santa-Rita et al., 2004, re-
ported the presence of multinucleated amastigotes within L.
amazonensis-infected macrophages which were treated
in vitro with MIL [55]. In the present study, TEM examination
of the parasite mitochondrion showed that its size and mem-
brane integrity were preserved. In contrary, Santa-Rita et al.,
2004, revealed the swelling of the mitochondrion with loss of
its inner membrane organization in MIL-in vitro-treated L.
amazonensis amastigotes, which denoted the structural affec-
tion of the parasitic mitochondrion in response to MIL ther-
apy [55]. Current results are in agreement with Luque-Ortega
and Rivas, 2007, who reported no structural alteration of the
parasite mitochondrion although that it could be functionally
affected (mitochondrial dysfunction) by MIL [56]. In their
study, they revealed inhibition of cytochrome oxidase enzyme
and intracellular ATP synthesis, together with reduction of
oxygen consumption and mitochondrial depolarization after
overnight in vitro incubation of L. donovani promastigotes with
MIL [56].
In the present study, pyknosis of infectedmacrophage nucleus
was observed. It appeared as shrinkage of nucleus with condensa-
tion of the nuclear chromatin that denotes degeneration of the af-
fected cell. Such ﬁndingmight reveal extension ofMIL activity to
involve Leishmania infected host cells by induction of macro-
phage cell degeneration.However, ina studyconductedbyVerma
and Dey, 2004, to clarify the possible mechanism of MIL-medi-
ated death ofL. donovani, they reported thatMIL causes no dam-
age to infected macrophage nuclei [42].
In conclusion, the present study revealed activity of MIL
against experimental Old World CL in the mouse model
caused by L. major (MHOM/IL/81/FEBNI), one of the caus-
ative species of CL in the Middle East.
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